Effect of metformin on bone mineral density, insulin resistance and cytokines in type 2 diabetes mellitus patients with primary hypertension

Abstract

Abstract:

AIM: To investigate the changes of bone mineral density （BMD）, insulin resistance (IR) and cytokines in type 2 diabetes mellitus (T2DM) patients with primary hypertension． METHODS: 125 patients of T2DM patients with primary hypertension were randomly divided into Gliclazide plus melformin group (treatment group) and Gliclazide group(control group )．BMI, fasting blood glucose（FPG）, hemoglobin A1c（HbA1c）, fasting insulin(FINS), the index of insulin resistance（HOMA-IR）, adiponectin(APN), 1eptin(LEP), tumor necrosis factor-α(TNF-α), interleukin-6（IL-6）, insulin-like growth factor-1(IGF-1) and BMD of the lumbar vertebrae 2-4（L2-4）and the left femofal neck were measured and compared．RESULTS:（1）After treatment for 12 weeks，levels of FPG and HbA1c decreased in both groups (P<0.05)；BMI decreased compared with before therapy in treatment group (P<0.05).（2）Compared with before therapy and control group，levels of APN, IGF-1 and BMD of the L2-4 and the left femofal neck increased in treatment group(P<0.05)，levels of FINS, HOMA-IR, TNF-α and IL-6 decreased(P<0.05)；LEP decreased compared with before therapy (P<0.05)，but there was no significant difference after therapy between groups（P>0.05）.（3）The BMD of the L2-4 and the left femofal neck were positively correlated with the APN and IGF-1，yet negatively correlated with the HOMA-IR, LEP, TNF-α and IL-6. CONCLUSION: Metformin can improve BMD, IR and correct dysfunction of cytokines in T2DM patients with primary hypertension，which may reduce risk of osteoporosis and fracture.

Key words: type 2 diabetes mellitus, hypertension, etformin, bone mineral density, insulin resistance, cytokines

CLC Number:

R587.2

SONG Meiqing. Effect of metformin on bone mineral density, insulin resistance and cytokines in type 2 diabetes mellitus patients with primary hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 694-698.

References

［1］Kurra S，Siris E. Diabetes and bone health: the relationship between diabetes and steoporosis-associated fractures［J］. Diabetes Metab Res Rev，2011，27: 430-435.
［2］Yang S，Nguyen ND，Center JR，et al．Association between hypertension and fragility fracture：a longitudinal study［J］. Osteoporos Int, 2014, 25(1):97 -103.
［3］Elizabeth BC，Ｄonna KS．Does hyperinsuline mia preserve bone［J］？ Diabetic Care，2000，19：1388-1389．
［4］Gotoh M，Mizuno K，Ono Y，et al．High blood pressure，bone mineral loss and insulin resistance in women［J］．Hypertens，Res，2005，28（7）：565-570．
［5］Mirza S,Hossain M,Mathews C, et al．Type 2 diabetes is associated with elevated level of TNF-alpha,IL-6 and adipoectin and low levels of leptin in a population of Mexican Americans:a cross-sectional study［J］.Cytokine, 2012, 57:136-142.
［6］李运启.绝经后高血压患者血清脂联素和炎性细胞因子水平与骨密度的相关性研究［J］.临床合理用药，2015，8(5C)：107-108．
［7］Borges JL, Bilezikian JP, Jones-Leone AR, et al.A randomized,parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naive type 2 diabetes mellitus patients［J］. Diabetes Obes Metab，2011,13(11):1036-1046.
［8］张彬，黄碧坤，王旭明，等.二甲双胍和辛伐他汀联用药对糖尿病大鼠骨密度变化的实验研究［J］. 中国骨质疏松杂志,2013,19(7): 661-664.
［9］栾峰，刘财德.二甲双胍对2型糖尿病患者骨质疏松影响到临床研究［J］.大家健康,2014,8(10):521.
［10］王运林，罗卓章.二甲双胍和吡格列酮对男性2型糖尿病患者骨代谢指标的影响［J］. 临床内科杂志,2011,28(8): 524-526.
［11］甄东户，刘丽娟，成建国,等. 二甲双胍对糖基化终末产物诱导的成骨细胞氧化应激和凋亡的影响［J］.中国临床药理学与治疗学,2013,7：743-748.
［12］崔冉，曲伸.糖尿病性骨质疏松［J］．药品评价，2015，12（15）：16-21.
［13］Elizabeth BC，Ｄonna KS．Does hyperinsuline mia preserve bone ［J］？Diabetic Care，2000，19：1388-1389．
［14］刘财德，柳蕾，鹿跟涛．2型糖尿病患者骨密度与胰岛素抵抗关系的研究［J］．潍坊医学院学报，2014，36（4）：251-253.
［15］Gotoh M，Mizuno K，OnoY，et al．High blood pressure，bone mineral loss and insulin resistance in women［J］．Hypertens Res，2005，28（7）：565-570．
［16］Singla R，Goyal A，Bedi GK，et al. Study of serum insulin levels in patients of euglycemic essential hypertension：a cross sectional study in North Indian population［J］．Diabetes Metab Syndr，2013，7（4）：202-205.
［17］薄德峰，李瑞霄，曹文功,等.2型糖尿病合并骨质疏松患者胰岛素样生长因子1水平变化［J］.临床荟萃，2014,29(12):1411-1413.
［18］李鸿娟,张东辉,刘海津.吡格列酮联合二甲双胍对2型糖尿病患者胰岛素抵抗及脂肪细胞因子水平的影响［J］.中国老年学杂志，2014，34(5): 2416-2418.
［19］Fidan E，Onder Ersoz H,Yilmaz M,et al.The effects of rosiglitazone and metfomain on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus［J］．Acta Diabetol，201l，48：297-302.
［20］汤佳珍，况荣华，杨治芳,等. 2型糖尿病患者IGF-1水平及二甲双胍治疗对其的影响［J］.实用临床医学，2009,10(6): 46-47.

[1]	MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu. Correlation between 25(OH)D and metabolically related fatty liver in T2DM population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
[2]	HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu. Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382.
[3]	NING Sisi, ZHAO Yuhong, YAN Lei, TANG Minna, ZHANG Ningzhi, ZHANG Yongqiao, CUI Zhaoqiang. Controversies over the targets of controlling blood pressure in hyper- tensive patients with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 463-467.
[4]	WANG Jie, LI Long, CHEN Feng, LIU Shengfei. Research progress of metformin in the pathogenesis of pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 235-240.
[5]	MA Yitong, MA Jianhong, GAO Yating, LIU Chang. Pathogenic mechanism and research progress of adipocytokines in endometrial cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1315-1320.
[6]	ZHAO Yangting, CHEN Chongyang, PAN Binjing, LV Xiaoyu, LIU Jingfang. Trimethylamine N-oxide: the potential target for osteoporosis treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1161-1167.
[7]	SHEN Chang, AI Kelong, HU Changping. Research progress in the regulation of hypoxic pulmonary hypertension by hypoxia-inducible factor-1 signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 114-120.
[8]	WANG Xin, LIU Weiying, WU Chen, KAI Jinjun, LIANG Xuejie, CHANG Yingxuan. Metformin regulates AMPK/SREBP-1 pathway and its clinical application [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1049-1054.
[9]	ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen. Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
[10]	FU Hong, TIAN Lei. Individualized precision therapy for patients with ischemic stroke and hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 870-876.
[11]	CHEN Wengang, YIN Qin, ZHANG Weiwei, ZHOU Lulu, KOU Wanqing, YUAN Xiaolong. Distributions of MTHFR gene polymorphism and its correlation with blood Hcy in patients with hypertension in southern Anhui province [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 768-774.
[12]	LU Senlin, LIU Xinyuan, WANG Jili, HUANG Xiaofei. Research progress of virus-mediated gene therapy in type 2 diabetes mellitu [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 800-807.
[13]	WANG Zhen, QUAN Haiyan, HONG Chenliang, YUAN Lijialong, QIN Xuping. Swimming improves renal function of diabetic mice by promoting autophagy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 632-638.
[14]	GAO Jiarong, SHI Miaomiao, CHEN Hao, JIANG Hui, QIN Xiujuan. Effect of Qiteng Xiaozhuo granule mediating miR-339-5p on inflammatory indexes in rats with chronic glomerulonephritis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 457-465.
[15]	ZHANG Ningzhi, ZHAO Yuhong, TANG Minna, ZHANG Yongqiao, NING Sisi, CUI Zhaoqiang. Application of chronopharmacology in the hypertension treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 418-422.